Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG-3
2025-521284-12-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Zongertinib adjuvant monotherapy with Standard of care adjuvant treatment or observation (2 arms). Primary endpoint: Disease-free survival. Planned start Mar 2026; status: authorised.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521284-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521284-12-00.